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Efficacy of Combination of Immunotherapies in a Murine in a Murine Squamous Cell Carcinoma
Model
Introduction: Head and neck squamous cell carcinomas (HNSCCs) are a type of neoplasm found
in the epithelium of the oral cavity, oropharynx, nasopharynx, larynx, or hypopharynx. Recent
evidence has demonstrated that 70-90% of HNSCC are associated with Human Papillomavirus
(HPV), particularly strain 16 producing oncogenic proteins E6/E7. 1 Currently, HNSCCs are treated
with surgery, chemotherapy, and radiation, however immunotherapy with immune checkpoint
(PD-1) blocking agents promises to improve outcomes in HNSCC.2
Objective: This study examined the therapeutic effects of dual and triple combination
immunotherapies in a mouse model of HPV-associated HNSCC.
Methods: Treatment modalities included a tumor vaccine (attenuated Listeria monocytogenes
based vaccine encoding HPV16 E6/E7 (AXAL)), an immune checkpoint inhibitor targeting PD1
(RMP1-14) and topical subtherapeutic radiation. Mice were injected subcutaneously with tumor
cells expressing HPV16 E6/E7 (TC-1). When tumors were established, mice were vaccinated with
AXAL (3 injections) either alone and/or with anti-PDi and/or with a single dose of radiation.
Results: Partial responses were observed in some mice receiving dual combination therapies.
Most mice treated with triple immunotherapy revealed complete tumor regression.
Discussion: Combination immunotherapy is effective in the TC-1 HNSCC model system. The
results obtained set the stage for investing immune mechanism underpinning treatmentassociated tumor regression.
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